Ischemic Stroke
Conditions
Keywords
Post Intensive Care Unit Syndrome, Ischemic stroke
Brief summary
Post intensive care syndrome (PIC syndrome) is an important problem in modern intensive care strategy. Understanding the mechanisms of PIC syndrome helps prevent it in patients with respiratory, neuromuscular transmission, and cognitive impairments that require prolonged support of vital functions. Significant role in the formation and severity of PIC syndrome is played by the severity of the systemic inflammatory response, which is an individual reaction of the body, and this determines the degree of neurological and psychological deficits. Chronic diseases such as diabetes mellitus, especially in the context of metabolic syndrome, worsen the course of PIC syndrome and delays recovery. Early initiation of rehabilitation measures in the intensive care unit and subsequent expansion of the individual rehabilitation program contributes to the rapid and successful recovery of not only vital functions, but also cognitive, motor and emotional disorders. This shortens the hospital stay of patient and improves their quality of life after discharge.
Interventions
None listed
Sponsors
POLYSAN Scientific & Technological Pharmaceutical Company
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Men and women over 18 years of age and older; * Stay in the ITU and (or) intensive care unit for at least 3 days; * Diagnosed post intensive care syndrome (PIC syndrome) with moderate-to-severe severity \>3\<6 points * Diagnosed modalities critical illness polyneuropathy, respiratory neuropathy, dysphagia of the domain Neuromuscular complications of PIC syndrome at 2-3 stages of the rehabilitation route at any value of PICS severity index * Diagnosed modalities decreased gravitational gradient, decreased exercise tolerance in the domain Vegetative-metabolic complications at 2-3 stages of the rehabilitation route at any value of PICS severity index
Exclusion criteria
* Premorbid level of vital activity when assessed on the rehabilitation routing scale 4-5 points; * Hematocrit ≤30%; * Hemoglobin level ≤80 g/L; * Acute cardiac failure; * Acute respiratory failure; * Acute renal failure; * Acute liver cell failure; * Use of drugs from metabolic agents pharmacotherapeutic group at the time of inclusion in the study * Life expectancy of 6 months or less or presence of incurable diseases in decompensation stage
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Dynamics of rehabilitation routing status score | day 12, day 30, day 60, day 90 | Dynamics of rehabilitation routing status score from the start of the study (Visit 1) to Visit 3, Visit 4, Visit 5 and Visit 6 measured in both groups |
| Dynamics of Barthel status score | day 12, day 30, day 60, day 90 | Dynamics of Barthel status score from the start of the study (Visit 1) to Visit 3, Visit 4, Visit 5 and Visit 6 measured in both groups |
| Dynamics of EQ5 status score | day 12, day 30, day 60, day 90 | Dynamics of EQ5 status score from the start of the study (Visit 1) to Visit 3, Visit 4, Visit 5 and Visit 6 measured in both groups |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Dynamics of somatic status | day 12, day 30, day 60, day 90 | Dynamics of somatic status from the start of the study (Visit 1) to Visit 3, Visit 4, Visit 5 and Visit 6 measured in both groups |
| Dynamics of rehabilitation status | day 12, day 30, day 60, day 90 | Dynamics of rehabilitation status from the start of the study (Visit 1) to Visit 3, Visit 4, Visit 5 and Visit 6 measured in both groups |
Other
| Measure | Time frame | Description |
|---|---|---|
| Identification during the event related monitoring of responders and non-responders | day 12, day 30, day 60, day 90 | Identification during the event related monitoring of responders and non-responders for the use of cytoflavin for adjunctive drug modulation in PIT syndrome rehabilitation |
Countries
Russia
Contacts
Primary ContactAndrey Belkin, MD
Outcome results
None listed